Vitespen
Identification
- Generic Name
- Vitespen
- DrugBank Accession Number
- DB06400
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Endoplasmin (human tumor rejection antigen 1)
- Heat shock protein-peptide complex-96 vaccine
- Oncophage
- Vitespen
- External IDs
- HSPPC 96
- HSPPC-96
- HSPPC96
Pharmacology
- Indication
Investigated for use/treatment in kidney cancer, melanoma, renal cell carcinoma, lymphoma (unspecified), colorectal cancer, and brain cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
HSPPC-96 is a protein peptide complex consisting of a 96 kDa heat shock protein (Hsp), gp96, and an array of gp96-associated cellular peptides. Immunisation with HSPPC-96 induces T-cell specific immunity against these peptides; gp96 is not immunogenic per se. The non-covalent binding of gp96 to peptides is neither selective nor restricted to cell types. Thus, the collection of gp96-associated peptides represents the antigenic peptide pool of a cell; this is the basis of the peptide-specific immunogenicity elicited by HSPPC-96.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Vitespen can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of Vitespen can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Vitespen can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Vitespen can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Vitespen can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- H3598Y1TLJ
- CAS number
- 492448-75-6
References
- General References
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Malignant Melanoma 1 3 Completed Treatment Renal Cell Carcinoma (RCC) 1 3 Terminated Treatment Renal Cancer / Renal Cell Carcinoma (RCC) 1 2 Completed Not Available Lung Cancer / Non-Small Cell Lung Carcinoma 1 2 Completed Treatment Brain and Central Nervous System Tumors 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Drug created at March 19, 2008 16:29 / Updated at September 19, 2023 04:36